5/5/2014 9:48:06 AM
WATERTOWN, Mass. & AMSTERDAM--(BUSINESS WIRE)--FORMA Therapeutics and The Netherlands Cancer Institute (NKI) announced today a collaborative initiative and exclusive license agreement in which FORMA has acquired a unique covalent chemistry platform developed by Huib Ovaa, Ph.D., Principal Investigator, Chemical Biology Laboratories at NKI and a member of FORMA’s deubiquitinase (DUB) investigator network. Under this collaborative initiative, FORMA and Dr. Ovaa will advance the research, discovery and clinical application of highly-selective, irreversible therapeutics. This represents a distinct and additional agreement between FORMA Therapeutics and Dr. Ovaa, with the first agreement announced in the area of DUBs on July 9, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by